The standard medical approach of developing single therapeutics for single targets is ineffective for aging because multiple age-related diseases are interconnected and arise simultaneously.

Linkgevity has identified a first-in-class drug to target unregulated cell death (necrosis) and plans to take it into Phase 2 clinical trials with the UK's National Health Service.

Kidney disease accounts for 24% of Medicare's annual budget.